Aprea Presents Preclinical Data at AACR
News Apr 11, 2013
Aprea AB has presented preclinical data at the American Association for Cancer Research (AACR) meeting in Washington, DC, USA.
The results from these studies show that Aprea’s lead candidate APR-246, a compound that reactivates mutant p53, acts synergistically with platinum compounds.
Aprea, which is part of the Karolinska Development portfolio, is now preparing a Phase II study with APR-246 in platinum resistant ovarian cancer.
The title of Aprea’s poster presentation at AACR was “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients”.
In the studies, the anticancer effect of APR-246 alone, and in combination with platinum compounds, on ovarian cancer cells were investigated.
The results show that APR-246 acts synergistically with platinum compounds and reverses the cisplatin-sensitivity to cisplatin-resistant p53 mutant ovarian cancer cells.
Aberrations in p53 are common in many cancer forms and are associated with increased resistance to standard chemotherapy resulting in a poor prognosis for the patient. About 60% of ovarian cancer patients have p53 mutations.
Mikael von Euler, CMO of Aprea, commented; “We are very pleased with this comprehensive set of preclinical data supporting our planned Phase II study in platinum-resistant Epithelial Ovarian Cancer (EOC) patients who are candidates for further platinum-based chemotherapy. APR-246 has the potential to be an important new treatment for these patients with high unmet medical need”.
Discovery Advances Efforts to Prevent Spread of CancerNews
Newly identified gene targets could be key to preventing the spread of cancer, new University of Alberta research has shown.
Higher BMI is Associated with a Lower Risk of Breast Cancer Before MenopauseNews
Having a higher body mass index (BMI) at a younger age is associated with a decreased risk of developing breast cancer before the menopause, major new research funded by Breast Cancer Now and other collaborators has found.READ MORE
Miniature Testing of Drug Pairs on Tumor BiopsiesNews
Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device. The research marks the latest advancement in the field of personalised medicine. Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments.READ MORE